Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23990304 | 0.91 | CYP2A6 (0.53) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15006444 | 0.86 | HTR2C (0.56) | CYP2A6HTR2CCYP11B2 | |
| SCHEMBL28862286 | 0.85 | NOS3 (0.53) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23193878 | 0.79 | CYP2A6 (0.46) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17896813 | 0.78 | NOS3 (0.45) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26773906 | 0.78 | CYP2A6 (0.45) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26773912 | 0.78 | CYP2A6 (0.45) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26773908 | 0.78 | CYP2A6 (0.45) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL27724534 | 0.77 | CHRNB2 (0.53) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25112059 | 0.75 | CYP2A6 (0.46) | CYP2A6CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021222404-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN BIOTECH, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| EP-1838680-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006074940-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | CYP2A6 1085/4885CHRNB2 4472/4885CHRNB4 4574/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | CYP2A6 1085/4885CHRNB2 4472/4885CHRNB4 4574/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | CYP2A6 4669/4885CHRNB2 2563/4885CHRNB4 3289/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | CYP2A6 3600/4885CHRNB2 4542/4885CHRNB4 4698/4885 |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | BACE1, BACE2, APP | CYP2A6 1210/4885CHRNB2 1526/4885CHRNB4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.